Nadiya O Sydorenko

20110190239, Aug 4, 2011

Jul 1, 2009

13/000711

Young-Choon Moon - Belle Mead NJ, US
Nadiya Sydorenko - Piscataway NJ, US
Thomas Davis - South Orange NJ, US
Daniel J. Medina - Hampton NJ, US
Marites A. Rafanan - Woodbridge NJ, US

PTC THERAPEUTICS, INC. - South Plainfield NJ

A61K 31/655
C07D 471/04
C07D 487/04
A61K 31/437
A61K 31/506
A61K 31/519
A61P 35/00
A61P 35/02
A61P 37/02
A61P 29/00
A61P 33/06
A61P 31/12
A61P 31/00

514150, 546121, 544331, 544281, 514300, 514275, 5142591

The compounds, pharmaceutical compositions, and methods of using such compounds or compositions thereof described herein are useful for treating a disease modulated by B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein expression.

20210284660, Sep 16, 2021

Jun 25, 2019

17/254828

- South Plainfield NJ, US
Suresh Babu - Pennington NJ, US
Scott J. Barraza - Piscataway NJ, US
Anuradha Bhattacharyya - Edison NJ, US
Guangming Chen - Bridgewater NJ, US
Gary Mitchell Karp - Princeton Junction NJ, US
Andrew J. Kassick - Wexford PA, US
Anthony R. Mazzotti - Rahway NJ, US
Young-Choon Moon - Belle Mead NJ, US
Jana Narasimhan - Scotch Plains NJ, US
Nadiya Sydorenko - Princeton NJ, US
Anthony Turpoff - Hillsborough NJ, US
Matthew G. Woll - Dunellen NJ, US
Wuming Yan - Wayne NJ, US

C07D 519/00
C07D 417/14
C07D 513/04
C07D 487/04
C07D 471/04

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.In particular, the present description relates to substituted benzothiazole compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

20210275526, Sep 9, 2021

Nov 9, 2020

17/093194

- South Plainfield NJ, US
Anuradha Bhattacharyya - Edison NJ, US
Seongwoo Hwang - Edison NJ, US
Minakshi Jani - Iselin NJ, US
Young-choon Moon - Belle Mead NJ, US
Nadiya Sydorenko - Princeton NJ, US

A61K 31/506
A61K 31/433
C07D 403/14
C07D 405/14
C07D 401/12
C07D 417/14
C07D 417/04
C07D 487/04
C07D 401/04
C07D 409/14
C07D 487/10
C07D 237/20
C07D 471/10
C07D 413/14
C07D 487/08
C07D 405/12
C07D 403/10
C07D 471/08
C07D 403/12
C07D 417/10
C07D 401/14
C07D 417/12
A61K 31/50
A61K 31/415
A61P 25/28
A61K 31/4439
A61K 31/4709
A61K 31/501
A61K 31/517
A61K 31/5377
A61K 31/5513
G01N 33/68

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

20200163973, May 28, 2020

Jun 27, 2018

16/625081

- South Plainfield NJ, US
Minakshi B. Jani - Iselin NJ, US
Matthew G. Woll - Dunellen NJ, US
Nadiya Sydorenko - Princeton NJ, US

A61K 31/5513
A61P 25/00
A61K 31/519
A61K 31/5377

The present description relates to a method or use of a compound for treating or ameliorating HD (Huntington's Disease) in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I):or a form thereof, wherein w, w, w, w, w, wand ware as defined herein. In particular, the present description relates to a method of use of a compound of Formula (I) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering an effective amount of the compound or a form or composition thereof to the subject.

20200113904, Apr 16, 2020

Dec 11, 2019

16/710515

- South Plainfield NJ, US
Anuradha Bhattacharyya - Edison NJ, US
Seongwoo Hwang - Edison NJ, US
Minakshi Jani - Iselin NJ, US
Young-choon Moon - Belle Mead NJ, US
Nadiya Sydorenko - Princeton NJ, US

A61K 31/506
A61K 31/415
A61K 31/50
C07D 417/12
C07D 401/14
C07D 417/10
C07D 403/12
C07D 471/08
C07D 403/10
C07D 405/12
C07D 487/08
C07D 413/14
C07D 471/10
C07D 237/20
C07D 487/10
C07D 409/14
C07D 401/04
C07D 487/04
C07D 417/04
C07D 417/14
C07D 401/12
C07D 405/14
C07D 403/14
G01N 33/68
A61K 31/5513
A61K 31/5377
A61K 31/517
A61K 31/501
A61K 31/4709
A61K 31/4439
A61P 25/28
A61K 31/433

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

20200024260, Jan 23, 2020

Sep 26, 2019

16/583442

- South Plainfield NJ, US
Ramil Baiazitov - East Brunswick NJ, US
Liangxian Cao - East Brunswick NJ, US
Thomas W. Davis - South Orange NJ, US
Wu Du - Cranbury NJ, US
Ronggang Liu - Berwyn PA, US
Young-Choon Moon - Belle Mead NJ, US
Steven D. Paget - Hillsborough NJ, US
Hongyu Ren - Florence NJ, US
Nadiya Sydorenko - Princeton NJ, US
Richard Gerald Wilde - Somerville NJ, US

C07D 403/12
A61K 31/506
A61K 45/06
C07D 487/04
A61N 5/10
C07D 403/04
C07D 471/04

Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

20190000844, Jan 3, 2019

Dec 11, 2016

15/781303

- South Plainfield NJ, US
Anuradha Bhattacharyya - Edison NJ, US
Seongwoo Hwang - Edison NJ, US
Minakshi Jani - Iselin NJ, US
Young-choon Moon - Belle Mead NJ, US
Nadiya Sydorenko - Princeton NJ, US

A61K 31/506
A61K 31/501
A61K 31/4709
A61K 31/5513
A61K 31/5377
A61K 31/517
A61K 31/4439
A61K 31/433
A61P 25/28
G01N 33/68

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

20160297798, Oct 13, 2016

Nov 21, 2013

15/038039

- South Plainfield NJ, US
Ramil Baiazitov - East Brunswick NJ, US
Wu Du - Cranbury NJ, US
Chang-sun Lee - Belle Mead NJ, US
Young-Choon Moon - Belle Mead NJ, US
Steven D. Paget - Hillsborough NJ, US
Hongyu Ren - Dayton NJ, US
Nadiya Sydorenko - Princeton NJ, US

C07D 403/04
A61K 31/53
A61K 31/5377
C07D 413/14
C07D 401/14
C07D 405/14
A61K 45/06
C07D 471/04

Amine substituted triazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.